Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 29.28M P/E - EPS this Y 76.90% Ern Qtrly Grth -
Income -93.84M Forward P/E -0.59 EPS next Y 63.30% 50D Avg Chg -40.00%
Sales 8.68M PEG - EPS past 5Y - 200D Avg Chg -87.00%
Dividend N/A Price/Book 0.24 EPS next 5Y - 52W High Chg -97.00%
Recommedations 2.00 Quick Ratio 0.33 Shares Outstanding 28.43M 52W Low Chg 19.00%
Insider Own 7.66% ROA -28.57% Shares Float 26.56M Beta 1.92
Inst Own 11.36% ROE -258.99% Shares Shorted/Prior 709.47K/302.88K Price 1.28
Gross Margin -44.06% Profit Margin - Avg. Volume 1,299,820 Target Price 5.00
Oper. Margin -1,449.47% Earnings Date May 13 Volume 403,991 Change -1.54%
About VBI Vaccines, Inc.

VBI Vaccines Inc., a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus. In addition, it develops coronavirus vaccine candidates that include VBI-2902, VBI-2901, and VBI-2905. The company has collaboration and license agreements with Brii Biosciences Limited; and the National Research Council of Canada to develop pan-coronavirus vaccine candidate targeting COVID-19, severe acute respiratory syndrome, and Middle East respiratory syndrome. The company was formerly known as SciVac Therapeutics Inc. and changed its name to VBI Vaccines Inc. in May 2016. VBI Vaccines Inc. is based in Cambridge, Massachusetts.

VBI Vaccines, Inc. News
04/16/24 VBI Vaccines Reports Full Year 2023 Financial Results
04/11/24 VBI Vaccines Announces Closing of $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04/09/24 VBI Vaccines Announces $2 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
04/03/24 VBI Vaccines Presents Encouraging Early Tumor Response Data From Randomized Controlled Phase 2b Study of VBI-1901 in Recurrent Glioblastoma
04/02/24 VBI Vaccines Announces Expanded Strategic Partnership with Canadian Government to Advance mRNA-Launched eVLP (MLE) Vaccine Platform
02/14/24 Strategic Licensing Agreements: Brii Bio’s Expansion into Chronic Disease Treatments with VBI Vaccines
02/14/24 VBI Announces Agreement to Sell Manufacturing Capabilities, Certain Related Assets, and Enter Into New License Agreement with Brii Biosciences
11/20/23 VBI Vaccines Presents Additional Biomarker Data from Phase 1/2a Study of VBI-1901 in Recurrent GBM at the 2023 Society for Neuro-Oncology (SNO) Annual Meeting
11/14/23 VBI Vaccines Reports Third Quarter 2023 Financial Results
10/26/23 VBI Vaccines Expands Proprietary Technology Platforms With Development of a Novel mRNA-Launched eVLP Vaccine Program
09/27/23 VBI Vaccines’ Pan-Coronavirus Vaccine Candidate, VBI-2901, Induced Broad and Durable Protective Titers Against Variants of Concern
09/07/23 VBI Vaccines Announces Dosing of First Patients in Phase 2b Study of VBI-1901 in Recurrent GBM
09/06/23 VBI Vaccines Partner Brii Biosciences Announces Topline Interim Results of Phase 2 Study Evaluating BRII-179 (VBI-2601) in Combination With PEG-IFNα for the Treatment of Chronic Hepatitis B
08/14/23 VBI Vaccines Reports Second Quarter 2023 Financial Results
08/03/23 Puma Biotech (PBYI) Surpasses Q2 Earnings and Revenue Estimates
07/24/23 VBI Vaccines Announces Closing of Underwriters’ Partial Exercise of Option to Purchase Additional Common Shares
07/19/23 VBI Vaccines Announces PreHevbri® is Now Available in the Netherlands and Belgium for the Prevention of Hepatitis B in Adults
07/13/23 7 Biotech Stocks to Sell in July
07/06/23 VBI Vaccines Announces Pricing of $18 Million Public Offering and $3 Million Concurrent Registered Direct Offering
07/05/23 VBI Vaccines Announces Proposed Concurrent Public Offering and Registered Direct Offering of Common Shares and Warrants
VBIV Chatroom

User Image IamVocabulary Posted - 4 hours ago

$VBIV piece of shit stock will be delisted soon and screw us even more. The management decisions have been nothing short of criminal.

User Image DaytradeX Posted - 10 hours ago

$VBIV time to buy 🕰

User Image Tiger10 Posted - 11 hours ago

$VBIV hello hi yes just one question what the fuck

User Image Newbombturk Posted - 15 hours ago

$AMC $GME $VBIV $MULN best post this month : https://stocktwits.com/spd4961/message/570767311

User Image AccuRoger Posted - 1 day ago

$VBIV Congrats, VBI is presenting at ASCO. However, it is the same information released by PR a few days ago. https://meetings.asco.org/abstracts-presentations/238302

User Image Newbombturk Posted - 1 day ago

$VBIV https://chartexchange.com/symbol/nasdaq-vbiv/exchange-volume/

User Image Newbombturk Posted - 1 day ago

$AMC $gme $VBIV https://www.youtube.com/watch?v=4b53Yxs_HaI

User Image intratio Posted - 2 days ago

$VBIV Our algorithm is forecasting the market value of this company has a positive short-term outlook and the stock price is consistent with the company s long-term fundamentals

User Image Newbombturk Posted - 2 days ago

$VBIV the US stock stock market : https://chartexchange.com/symbol/nasdaq-vbiv/exchange-volume/

User Image Tiger10 Posted - 2 days ago

$VBIV ass in the purest form

User Image suphawk85 Posted - 3 days ago

$VBIV @Tiger10 I thought it was a money bonfire.

User Image Tiger10 Posted - 3 days ago

$VBIV this a stock or a garbage disposal??

User Image NoToConArtists Posted - 3 days ago

$VBIV low volume bullshit on Nasdaq casino today (still legal)

User Image Tiger10 Posted - 4 days ago

$VBIV good news: Extension is basically guaranteed now (unless they plan on being delisted lol) because even with a RS they wouldn’t have 10 days above $1 to meet compliance. My thoughts: I see multiple pumps above $1 with multiple mini dilutions until MLE partnership with upfront capital is announced. Nearing the middle/end of the 6 month extension the stock will be trading well above $1. Likely in the $200M market cap range if GBM data is good. Whatever SP that will equate to I’m not sure. Anyways, should be a better summer than last year. GL! I troll a lot on here but I’m still a bull through and through with 45K shares.

User Image cs999 Posted - 6 days ago

$VBIV just another rotten week of hell

User Image Tiger10 Posted - 6 days ago

$VBIV Bev gritting her teeth at my 30k still being invested here

User Image makeithappen Posted - 6 days ago

$VBIV @GooseIsGod Goose we desperately need you back here! Your replacement is a bummer Bev, nobody likes a bummer Bev. Don't be like a Bev, be like a Goose 🪿 or a Tiger 🐅

User Image realbrewhaha Posted - 6 days ago

$VBIV fake.

User Image Tiger10 Posted - 6 days ago

$VBIV Bev have another coffee girl. Love when she gets all worked up like this

User Image NoToConArtists Posted - 6 days ago

$VBIV blahblah

User Image ThreeGirls Posted - 6 days ago

$VBIV Everyone whining I’m simply the bearer or bad news. So here it is, GOOD news, and potentially very GOOD news. I have shown you how NASDAQ’s granting a 180 extension this time around is not a slam dunk, anything but, because of primarily 2 consideration which were NOT present last time: 1. VBI is in considerably WORSE shape than 12/22 and we’re forced into RS anyway. And Financial concerns are 1 of the nasdaq considerations 2. They look at past delisting events. This is the 3rd, and the second in 2 years which needs an extension. Absent other conditions, I think VBI this time around is in considerable risk of not being granted an extension, and be forced into a RS. But VBI, per nasdaq protocol is is now or has already made their case for an extension. If they are granted an extension, I believe it’s because VBI has shared with them some pending news that has a high likelihood of happening in the near term. Read my reply for what that is.

User Image ThreeGirls Posted - 1 week ago

$VBIV VBI has 11 days to regain compliance with nasdaq. To avoid delisting VBI must close above $1.00 for 10 consecutive days. As of today that it is not possible with only 7 trading days left til April 29. This is the 3rd time VBI was issued a delisting letter. The first in 2019. VBI achieved compliance without an extension in early January 2020. This is the 2nd time VBI will not meet compliance after 180 days (12/29/22). Back then VBI was given a 180 days extension At the time that extension was granted, VBI closed the the year with $63M in cash and had just closed a refinanced debt facility of up to $100 million with K2 adding $20 million of non-dilutive funding to the balance sheet. They had over $450M of potential royalty and milestones coming from Brii. They had 1901 rights worldwide So how are things different today? And why that's important? read my reply

User Image Can171970 Posted - 1 week ago

$VBIV $VBIV SG&A expenses for the full year 2023 were $42.1 million and revenue of $8,7 million. This company is still start-up phase and will not be 9-10 $ in a short period, but can be manipulated to drain more money from all investors. Revenue should 10x at least, it means wait until 2027. They will need more sales channel to sell more why DD is searched for. The rest is full of clowns to attack you when you write right things here. I am investing on it for a long time expectation because their product functionality and top management knowledge. It is the right time enter small amount then 10%-20-% reductions in stock price.

User Image makeithappen Posted - 1 week ago

$VBIV Honestly I miss having Goose around. Much more entertaining then Bev 😢

User Image AccuRoger Posted - 1 week ago

$VBIV The cheerleaders on this message board used to pump Preceptive as the genesis fund to rationalize going all in with VBI. Well, they no longer hold more than 5% of the shares. Not due to selling. Instead, the ATM and direct sales of stock over the past few weeks diluted the genesis fund’s holdings. See the SEC filing today based on 28 million outstanding shares that does not count the over 16 million in warrants that carry a low exchange price of 76 CENTS. Quote “On April 16, 2024, the Reporting Persons ceased being holders of 5% or more of the outstanding shares of the Issuer’s Common Shares.” At least many on here are not alone, sadly.

User Image ThreeGirls Posted - 1 week ago

$VBIV If you are like most here, you are hoping for an event that will fend off delisting from NASDAQ, avoid having to do a RS, avoid having to do a raise after a RS, or avoid K2 declaring a foreclosure. Raising significant cash absent going to the capital markets will resolve all this. A large equity investment or a sale of an asset would help, but the best way to eliminate the constant hang over a precipice, is a significant deal; license and/or partnership for the remaining 4 assets; PHB, COVID, 1901, or MLE. I have said it many times, "they have to do something". No one here is in disagreement. What hasn't changed is that precipice. As it always has been, its CASH. For anyone to disagree with that, they should explain trading at 2 cents pre-split, 60 cents today. Until that is resolved, things wont change or get worse. There are 2 events pending fro VBI that investors should watch. Read my reply for the facts YOU need to know...

User Image Tiger10 Posted - 1 week ago

$VBIV where the heck is Bev at. I need to know how much cash they will have on hand on June 13th at 3:36pm ET.

User Image cs999 Posted - 1 week ago

$VBIV typical monkey business baxter

User Image Thepark88 Posted - 1 week ago

$VBIV updated corporate preso - hanging their hat in a MLE partnership https://www.vbivaccines.com/wp-content/uploads/2024/04/VBI-Corporate-Overview-April-2024.pdf

User Image sirloud13 Posted - 1 week ago

$VBIV

Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
GILLIS STEVEN Director Director Jul 10 Buy 1.65 609,090 1,004,998 1,043,292 07/18/23
PERCEPTIVE ADVISORS LLC 10% Owner 10% Owner Apr 04 Sell 0.13 10,894,749 1,416,317 41,440,729 04/06/23